Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved

Lexicon Pharmaceuticals, Inc. LXRX announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.  The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, lead investigator in the recently completed study.